KR20080095902A - 단백질 키나제의 억제제로서 유용한 디하이드로디아제핀 - Google Patents
단백질 키나제의 억제제로서 유용한 디하이드로디아제핀 Download PDFInfo
- Publication number
- KR20080095902A KR20080095902A KR1020087022521A KR20087022521A KR20080095902A KR 20080095902 A KR20080095902 A KR 20080095902A KR 1020087022521 A KR1020087022521 A KR 1020087022521A KR 20087022521 A KR20087022521 A KR 20087022521A KR 20080095902 A KR20080095902 A KR 20080095902A
- Authority
- KR
- South Korea
- Prior art keywords
- aliphatic
- compound
- formula
- optionally substituted
- cyclopentyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000001253 Protein Kinase Human genes 0.000 title claims abstract description 37
- 108060006633 protein kinase Proteins 0.000 title claims abstract description 37
- 239000003112 inhibitor Substances 0.000 title abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 338
- 150000001875 compounds Chemical class 0.000 claims abstract description 247
- 239000000203 mixture Substances 0.000 claims abstract description 95
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 64
- 230000008569 process Effects 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 384
- -1 anti-nerve factor Substances 0.000 claims description 166
- 125000001931 aliphatic group Chemical group 0.000 claims description 108
- 125000002723 alicyclic group Chemical group 0.000 claims description 53
- 125000002950 monocyclic group Chemical group 0.000 claims description 52
- 125000003118 aryl group Chemical group 0.000 claims description 48
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 229920006395 saturated elastomer Polymers 0.000 claims description 35
- 125000005843 halogen group Chemical group 0.000 claims description 34
- 229910052799 carbon Inorganic materials 0.000 claims description 33
- 125000005842 heteroatom Chemical group 0.000 claims description 33
- 229910052757 nitrogen Inorganic materials 0.000 claims description 33
- 229910052717 sulfur Inorganic materials 0.000 claims description 33
- 125000004429 atom Chemical group 0.000 claims description 32
- 229910052760 oxygen Inorganic materials 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 28
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 108010056274 polo-like kinase 1 Proteins 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 22
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 21
- 230000001404 mediated effect Effects 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 230000002062 proliferating effect Effects 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 12
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 11
- 206010025323 Lymphomas Diseases 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 238000007363 ring formation reaction Methods 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 8
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 8
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 239000003981 vehicle Substances 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 230000011278 mitosis Effects 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 208000020084 Bone disease Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 230000001028 anti-proliverative effect Effects 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 239000002327 cardiovascular agent Substances 0.000 claims description 2
- 229940125692 cardiovascular agent Drugs 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 150000001409 amidines Chemical class 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 45
- 238000002360 preparation method Methods 0.000 abstract description 23
- 238000011282 treatment Methods 0.000 abstract description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 777
- 238000004128 high performance liquid chromatography Methods 0.000 description 282
- 201000006417 multiple sclerosis Diseases 0.000 description 275
- 239000003153 chemical reaction reagent Substances 0.000 description 273
- 238000005481 NMR spectroscopy Methods 0.000 description 271
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 37
- 235000002639 sodium chloride Nutrition 0.000 description 32
- 239000002904 solvent Substances 0.000 description 31
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 27
- 238000003556 assay Methods 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 27
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 26
- 150000003839 salts Chemical class 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 21
- 108091000080 Phosphotransferase Proteins 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- 102000020233 phosphotransferase Human genes 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 239000007788 liquid Substances 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 15
- 201000009030 Carcinoma Diseases 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 208000009956 adenocarcinoma Diseases 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 238000006880 cross-coupling reaction Methods 0.000 description 13
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 238000005859 coupling reaction Methods 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 206010039491 Sarcoma Diseases 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 229910019142 PO4 Inorganic materials 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- PKVNVXXWANAAFP-UHFFFAOYSA-N 1,7-dihydro-1,4-diazepin-6-one Chemical compound O=C1CNC=CN=C1 PKVNVXXWANAAFP-UHFFFAOYSA-N 0.000 description 8
- AZQDLBJZOAHSAZ-UHFFFAOYSA-N 1,7-dihydrodiazepin-6-one Chemical compound O=C1CNN=CC=C1 AZQDLBJZOAHSAZ-UHFFFAOYSA-N 0.000 description 8
- 101150011368 Plk2 gene Proteins 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000004770 neurodegeneration Effects 0.000 description 8
- 229910052763 palladium Inorganic materials 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- YQLWINMNFVBXQV-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC1=NC=C(N(C)C(=O)CCN2C3CCCC3)C2=N1 YQLWINMNFVBXQV-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 101150005816 PLK4 gene Proteins 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 230000003463 hyperproliferative effect Effects 0.000 description 7
- 101150067958 plk-3 gene Proteins 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000003909 protein kinase inhibitor Substances 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 239000001993 wax Substances 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 6
- 238000006069 Suzuki reaction reaction Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 101150003085 Pdcl gene Proteins 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 229940043355 kinase inhibitor Drugs 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 229940080469 phosphocellulose Drugs 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000000611 regression analysis Methods 0.000 description 5
- 238000013207 serial dilution Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- PSNIEFLRLSDKDM-UHFFFAOYSA-N 4-[(9-benzyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2CC=3C=CC=CC=3)C2=N1 PSNIEFLRLSDKDM-UHFFFAOYSA-N 0.000 description 4
- NHTJBDCHGVHNHO-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 NHTJBDCHGVHNHO-UHFFFAOYSA-N 0.000 description 4
- NGJOECBMVLIXBO-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[1-(hydroxymethyl)cyclopentyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2(CO)CCCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 NGJOECBMVLIXBO-UHFFFAOYSA-N 0.000 description 4
- OHKJKVBYFIWYPT-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)sulfanyl]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1SC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 OHKJKVBYFIWYPT-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 201000008808 Fibrosarcoma Diseases 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 206010024612 Lipoma Diseases 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 201000011066 hemangioma Diseases 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 201000010260 leiomyoma Diseases 0.000 description 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000000346 nonvolatile oil Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 201000002510 thyroid cancer Diseases 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- AKYWOSJCHOXPER-UHFFFAOYSA-N 2-(4-aminoanilino)-9-cyclopentyl-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC1=CC=C(N)C=C1 AKYWOSJCHOXPER-UHFFFAOYSA-N 0.000 description 3
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 3
- RRCJECRZJOIAPR-UHFFFAOYSA-N 3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-cyclopropylbenzamide Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=1)=CC=CC=1C(=O)NC1CC1 RRCJECRZJOIAPR-UHFFFAOYSA-N 0.000 description 3
- DLESGSRAZVKIHG-FQEVSTJZSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[2-[(3s)-3-fluoropyrrolidin-1-yl]ethyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCN2C[C@@H](F)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 DLESGSRAZVKIHG-FQEVSTJZSA-N 0.000 description 3
- AWMSNCZDEVVICA-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)CCN2C3CCCC3)C2=N1 AWMSNCZDEVVICA-UHFFFAOYSA-N 0.000 description 3
- OSKJUWWDWWGHNV-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]benzoic acid Chemical compound N1=C2N(C3CCCC3)CCC(=O)N(C)C2=CN=C1NC1=CC=C(C(O)=O)C=C1 OSKJUWWDWWGHNV-UHFFFAOYSA-N 0.000 description 3
- WWMYXBHGWNEGRQ-UHFFFAOYSA-N 4-[(9-cyclopropyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CC3)C2=N1 WWMYXBHGWNEGRQ-UHFFFAOYSA-N 0.000 description 3
- LUZHCQWNCOYFSK-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-(3-nitroanilino)-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC1=CC=CC([N+]([O-])=O)=C1 LUZHCQWNCOYFSK-UHFFFAOYSA-N 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 0 C(*1)[C@]1c1ccccc1 Chemical compound C(*1)[C@]1c1ccccc1 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 206010023825 Laryngeal cancer Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010043276 Teratoma Diseases 0.000 description 3
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 150000003951 lactams Chemical group 0.000 description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VQABXGLCIBLPOI-UHFFFAOYSA-N n-(2-chloropyridin-4-yl)-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC=2C=C(Cl)N=CC=2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 VQABXGLCIBLPOI-UHFFFAOYSA-N 0.000 description 3
- IKOYBKSNMRYXOZ-UHFFFAOYSA-N n-(cyanomethyl)-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC#N)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 IKOYBKSNMRYXOZ-UHFFFAOYSA-N 0.000 description 3
- QAJALZJPTGXLHN-UHFFFAOYSA-N n-(cyclopentylmethyl)-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC2CCCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 QAJALZJPTGXLHN-UHFFFAOYSA-N 0.000 description 3
- ANTWPJPZFVLZPS-MRXNPFEDSA-N n-cyclobutyl-4-[[(7r)-9-cyclopentyl-5,7-dimethyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzamide Chemical compound C([C@@H](C)C(=O)N(C)C1=CN=C(N=C11)NC2=CC=C(C=C2OC)C(=O)NC2CCC2)N1C1CCCC1 ANTWPJPZFVLZPS-MRXNPFEDSA-N 0.000 description 3
- VFQMKZZWWOPBKX-QGZVFWFLSA-N n-cyclopentyl-4-[[(7r)-9-cyclopentyl-5,7-dimethyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzamide Chemical compound C([C@@H](C)C(=O)N(C)C1=CN=C(N=C11)NC2=CC=C(C=C2OC)C(=O)NC2CCCC2)N1C1CCCC1 VFQMKZZWWOPBKX-QGZVFWFLSA-N 0.000 description 3
- OJMFTGXNNVNPKN-UHFFFAOYSA-N n-tert-butyl-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC(C)(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 OJMFTGXNNVNPKN-UHFFFAOYSA-N 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- JXYPNRIYAMXJSE-UHFFFAOYSA-N 1,4-diazepin-6-one Chemical compound O=C1C=NC=CN=C1 JXYPNRIYAMXJSE-UHFFFAOYSA-N 0.000 description 2
- HTSZQUVMTBELGW-UHFFFAOYSA-N 1-(1-hydroxypropan-2-yl)-5-methoxycyclohexa-2,4-diene-1-carboxamide Chemical compound COC1=CC=CC(C(N)=O)(C(C)CO)C1 HTSZQUVMTBELGW-UHFFFAOYSA-N 0.000 description 2
- ALOCUZOKRULSAA-UHFFFAOYSA-N 1-methylpiperidin-4-amine Chemical compound CN1CCC(N)CC1 ALOCUZOKRULSAA-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- AXLBOYZNEFYZBG-UHFFFAOYSA-N 2-(1,3-benzothiazol-6-ylamino)-9-cyclopentyl-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C=C4SC=NC4=CC=3)N=C2N1C1CCCC1 AXLBOYZNEFYZBG-UHFFFAOYSA-N 0.000 description 2
- LRLFTGOMOBGFBF-UHFFFAOYSA-N 2-(1h-benzimidazol-4-ylamino)-9-cyclopentyl-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C=4N=CNC=4C=CC=3)N=C2N1C1CCCC1 LRLFTGOMOBGFBF-UHFFFAOYSA-N 0.000 description 2
- HHJRAPWGDBLANS-UHFFFAOYSA-N 2-(3-aminoanilino)-9-cyclopentyl-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC1=CC=CC(N)=C1 HHJRAPWGDBLANS-UHFFFAOYSA-N 0.000 description 2
- MMTCECLUFNHCAD-UHFFFAOYSA-N 2-(3h-benzimidazol-5-ylamino)-9-cyclopentyl-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C=C4NC=NC4=CC=3)N=C2N1C1CCCC1 MMTCECLUFNHCAD-UHFFFAOYSA-N 0.000 description 2
- DDHPILNVQNHKAZ-UHFFFAOYSA-N 2-(benzylamino)-9-cyclopentyl-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NCC1=CC=CC=C1 DDHPILNVQNHKAZ-UHFFFAOYSA-N 0.000 description 2
- JSHFYWCAFVZVPH-UHFFFAOYSA-N 2-[(3-aminoindazol-1-yl)amino]-9-cyclopentyl-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NN3C4=CC=CC=C4C(N)=N3)N=C2N1C1CCCC1 JSHFYWCAFVZVPH-UHFFFAOYSA-N 0.000 description 2
- JORSMHDIYVAIGS-HXUWFJFHSA-N 2-[[4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzoyl]amino]ethyl (3r)-3-fluoropyrrolidine-1-carboxylate Chemical compound COC1=CC(C(=O)NCCOC(=O)N2C[C@H](F)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 JORSMHDIYVAIGS-HXUWFJFHSA-N 0.000 description 2
- BPDHNQGHQFTYME-UHFFFAOYSA-N 2-anilino-9-cyclopentyl-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC1=CC=CC=C1 BPDHNQGHQFTYME-UHFFFAOYSA-N 0.000 description 2
- MZFIBQFSRVWAAB-UHFFFAOYSA-N 2-chloro-5,7,7-trimethyl-8,9-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1CC(C)(C)C(=O)N(C)C2=CN=C(Cl)N=C21 MZFIBQFSRVWAAB-UHFFFAOYSA-N 0.000 description 2
- DVVYMNCRKNFABW-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1CC(=O)N(C)C2=CN=C(Cl)N=C2N1C1CCCC1 DVVYMNCRKNFABW-UHFFFAOYSA-N 0.000 description 2
- RSRPLYCCLBLNTJ-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-7,8-dihydro-5h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C12=NC(Cl)=NC=C2NC(=O)CCN1C1CCCC1 RSRPLYCCLBLNTJ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- OMEFBSBBCVEENU-UHFFFAOYSA-N 3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(NC=2N=C3N(C4CCCC4)CC(C)(C)C(=O)N(C)C3=CN=2)=C1 OMEFBSBBCVEENU-UHFFFAOYSA-N 0.000 description 2
- YCOCARUYLHCMGP-UHFFFAOYSA-N 3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-methyl-5-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC(C(=O)NC)=CC(NC=2N=C3N(C4CCCC4)CC(C)(C)C(=O)N(C)C3=CN=2)=C1 YCOCARUYLHCMGP-UHFFFAOYSA-N 0.000 description 2
- HUPOLWRZCJFKIJ-UHFFFAOYSA-N 3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(NC=2N=C3N(C4CCCC4)CC(C)(C)C(=O)N(C)C3=CN=2)=C1 HUPOLWRZCJFKIJ-UHFFFAOYSA-N 0.000 description 2
- AICPNZWOCKKNCH-UHFFFAOYSA-N 3-methoxy-n-methyl-4-[(5,7,7-trimethyl-6-oxo-9-phenyl-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C=3C=CC=CC=3)C2=N1 AICPNZWOCKKNCH-UHFFFAOYSA-N 0.000 description 2
- PGMLKIGFULHWHO-UHFFFAOYSA-N 3-methoxy-n-methyl-4-[(5,7,7-trimethyl-6-oxo-9-propan-2-yl-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C(C)C)C2=N1 PGMLKIGFULHWHO-UHFFFAOYSA-N 0.000 description 2
- JSGWYFSBRVDXKM-UHFFFAOYSA-N 3-methoxy-n-methyl-4-[[5,7,7-trimethyl-6-oxo-9-(2,2,3,3,3-pentafluoropropyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2CC(F)(F)C(F)(F)F)C2=N1 JSGWYFSBRVDXKM-UHFFFAOYSA-N 0.000 description 2
- MIDLUWHJXGZTHE-OAHLLOKOSA-N 3-methoxy-n-methyl-4-[[5,7,7-trimethyl-6-oxo-9-[(3r)-oxolan-3-yl]-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2[C@H]3COCC3)C2=N1 MIDLUWHJXGZTHE-OAHLLOKOSA-N 0.000 description 2
- SJNFUHUYRNXMRE-OAHLLOKOSA-N 3-methoxy-n-methyl-4-[[5,7,7-trimethyl-6-oxo-9-[(3r)-pyrrolidin-3-yl]-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2[C@H]3CNCC3)C2=N1 SJNFUHUYRNXMRE-OAHLLOKOSA-N 0.000 description 2
- MIDLUWHJXGZTHE-HNNXBMFYSA-N 3-methoxy-n-methyl-4-[[5,7,7-trimethyl-6-oxo-9-[(3s)-oxolan-3-yl]-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2[C@@H]3COCC3)C2=N1 MIDLUWHJXGZTHE-HNNXBMFYSA-N 0.000 description 2
- GJYJEKDFMSTNJO-UHFFFAOYSA-N 3-methoxy-n-methyl-4-[[5,7,7-trimethyl-9-(oxan-4-yl)-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCOCC3)C2=N1 GJYJEKDFMSTNJO-UHFFFAOYSA-N 0.000 description 2
- LQDAXECEYRLVDU-QGZVFWFLSA-N 3-methoxy-n-methyl-4-[[5,7,7-trimethyl-9-[(3r)-1-methylpiperidin-3-yl]-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2[C@H]3CN(C)CCC3)C2=N1 LQDAXECEYRLVDU-QGZVFWFLSA-N 0.000 description 2
- ZHRJVJZFEJZNFG-MRXNPFEDSA-N 3-methoxy-n-methyl-4-[[5,7,7-trimethyl-9-[(3r)-1-methylpyrrolidin-3-yl]-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2[C@H]3CN(C)CC3)C2=N1 ZHRJVJZFEJZNFG-MRXNPFEDSA-N 0.000 description 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- OANJCRFUTVVJHQ-UHFFFAOYSA-N 4-[(9-cyclobutyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCC3)C2=N1 OANJCRFUTVVJHQ-UHFFFAOYSA-N 0.000 description 2
- BVCQODYAEDBHRS-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-ethyl-n-methylbenzamide Chemical compound CCC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 BVCQODYAEDBHRS-UHFFFAOYSA-N 0.000 description 2
- LVCGCBHNTZDYOJ-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n,n-dimethylbenzamide Chemical compound COC1=CC(C(=O)N(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 LVCGCBHNTZDYOJ-UHFFFAOYSA-N 0.000 description 2
- SLUHTQGNFNMQFY-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-(1,2,2,6,6-pentamethylpiperidin-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CC(C)(C)N(C)C(C)(C)C2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 SLUHTQGNFNMQFY-UHFFFAOYSA-N 0.000 description 2
- PSHBHNFGGZOKBU-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-(1-methylazetidin-3-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CN(C)C2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 PSHBHNFGGZOKBU-UHFFFAOYSA-N 0.000 description 2
- IDXPDDLSXYFBLP-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-(1-propan-2-ylazetidin-3-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CN(C2)C(C)C)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 IDXPDDLSXYFBLP-UHFFFAOYSA-N 0.000 description 2
- QADDLVHYBPJAKY-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-(2-phenylethyl)benzamide Chemical compound COC1=CC(C(=O)NCCC=2C=CC=CC=2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 QADDLVHYBPJAKY-UHFFFAOYSA-N 0.000 description 2
- NZSUYLBDYYTBOG-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-(3,3,3-trifluoropropyl)benzamide Chemical compound COC1=CC(C(=O)NCCC(F)(F)F)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 NZSUYLBDYYTBOG-UHFFFAOYSA-N 0.000 description 2
- OPTFUKYPJGOPOM-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-(oxan-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCOCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 OPTFUKYPJGOPOM-UHFFFAOYSA-N 0.000 description 2
- MMUFEJDFODXCNF-NRFANRHFSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-[(3s)-1-propan-2-ylpyrrolidin-3-yl]benzamide Chemical compound COC1=CC(C(=O)N[C@@H]2CN(CC2)C(C)C)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 MMUFEJDFODXCNF-NRFANRHFSA-N 0.000 description 2
- SXHFJQHQBAKZAM-SFHVURJKSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-[(3s)-oxolan-3-yl]benzamide Chemical compound COC1=CC(C(=O)N[C@@H]2COCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 SXHFJQHQBAKZAM-SFHVURJKSA-N 0.000 description 2
- UHGOMPIUHMBZOI-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-phenylbenzamide Chemical compound COC1=CC(C(=O)NC=2C=CC=CC=2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 UHGOMPIUHMBZOI-UHFFFAOYSA-N 0.000 description 2
- OBMLGQDUHGEXIO-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-propan-2-ylbenzamide Chemical compound COC1=CC(C(=O)NC(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 OBMLGQDUHGEXIO-UHFFFAOYSA-N 0.000 description 2
- VQHIGBZOYAWLMG-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-propylbenzamide Chemical compound COC1=CC(C(=O)NCCC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 VQHIGBZOYAWLMG-UHFFFAOYSA-N 0.000 description 2
- LRJURAIIMHELTD-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 LRJURAIIMHELTD-UHFFFAOYSA-N 0.000 description 2
- KMHFUKMIIDYKDG-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-(1,3-dihydroxy-2-methylpropan-2-yl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC(C)(CO)CO)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 KMHFUKMIIDYKDG-UHFFFAOYSA-N 0.000 description 2
- RVXHSEQOUQIWSR-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-(1-hydroxy-2-methylpropan-2-yl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC(C)(C)CO)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 RVXHSEQOUQIWSR-UHFFFAOYSA-N 0.000 description 2
- JEJNWQDKCHRKNM-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-(2-fluoroethyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCF)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 JEJNWQDKCHRKNM-UHFFFAOYSA-N 0.000 description 2
- PDELTZDOFWVRRS-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-(2-hydroxyethyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCO)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 PDELTZDOFWVRRS-UHFFFAOYSA-N 0.000 description 2
- XDNSIABHIZBRPW-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-(3,3-difluorocyclobutyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CC(F)(F)C2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 XDNSIABHIZBRPW-UHFFFAOYSA-N 0.000 description 2
- UYLGWAIPBGPFFX-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-(3-hydroxybutyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCC(C)O)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 UYLGWAIPBGPFFX-UHFFFAOYSA-N 0.000 description 2
- UHDYMHOGHTYHEE-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-(cyclopropylmethyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC2CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 UHDYMHOGHTYHEE-UHFFFAOYSA-N 0.000 description 2
- MEFJJGDPXWULPU-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-(furan-2-ylmethyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC=2OC=CC=2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 MEFJJGDPXWULPU-UHFFFAOYSA-N 0.000 description 2
- WIUVZQNHOJRAPQ-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(1-hydroxycyclohexyl)methyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC2(O)CCCCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 WIUVZQNHOJRAPQ-UHFFFAOYSA-N 0.000 description 2
- FXTVYWYOVREDHO-XMMPIXPASA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(1r)-2,3-dihydro-1h-inden-1-yl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)N[C@H]2C3=CC=CC=C3CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 FXTVYWYOVREDHO-XMMPIXPASA-N 0.000 description 2
- VLDUQQDPFFDFFL-NFBKMPQASA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(1r,2r)-2-hydroxycyclohexyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)N[C@H]2[C@@H](CCCC2)O)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 VLDUQQDPFFDFFL-NFBKMPQASA-N 0.000 description 2
- CDZZRJYFCVTNSG-DENIHFKCSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(1r,2r)-2-hydroxycyclopentyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)N[C@H]2[C@@H](CCC2)O)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 CDZZRJYFCVTNSG-DENIHFKCSA-N 0.000 description 2
- POAYPMCXRNLTKV-UYAOXDASSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(1r,3r)-3-(hydroxymethyl)cyclopentyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)N[C@H]2C[C@H](CO)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 POAYPMCXRNLTKV-UYAOXDASSA-N 0.000 description 2
- AUCNIEUQDMWKNC-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(2,2-difluorocyclopropyl)methyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC2C(C2)(F)F)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 AUCNIEUQDMWKNC-UHFFFAOYSA-N 0.000 description 2
- DCQWJTDMJNHCKJ-OAQYLSRUSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(2s)-1-hydroxy-3-methylbutan-2-yl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)N[C@H](CO)C(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 DCQWJTDMJNHCKJ-OAQYLSRUSA-N 0.000 description 2
- BGXWEUSIZFATSU-SFHVURJKSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(2s)-2,3-dihydroxypropyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC[C@H](O)CO)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 BGXWEUSIZFATSU-SFHVURJKSA-N 0.000 description 2
- DYOORDNJHHVFBL-INIZCTEOSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(2s)-2-hydroxypropyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC[C@H](C)O)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 DYOORDNJHHVFBL-INIZCTEOSA-N 0.000 description 2
- UKCFGKCMCQEPBE-QFIPXVFZSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(3s)-1-(cyclopropylmethyl)pyrrolidin-3-yl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)N[C@@H]2CN(CC3CC3)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 UKCFGKCMCQEPBE-QFIPXVFZSA-N 0.000 description 2
- UIXCMIMWJGMBAQ-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[1-(2-fluoroethyl)piperidin-4-yl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CCN(CCF)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 UIXCMIMWJGMBAQ-UHFFFAOYSA-N 0.000 description 2
- BOMMEBIRSJFCKT-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[1-(cyclopropylmethyl)azetidin-3-yl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CN(CC3CC3)C2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 BOMMEBIRSJFCKT-UHFFFAOYSA-N 0.000 description 2
- VUCLBKNZSAHVIB-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[1-(cyclopropylmethyl)piperidin-4-yl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CCN(CC3CC3)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 VUCLBKNZSAHVIB-UHFFFAOYSA-N 0.000 description 2
- GACCQESUPVGTNQ-GBXCKJPGSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[[(1s,2r)-2-hydroxycyclohexyl]methyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC[C@H]2[C@@H](CCCC2)O)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 GACCQESUPVGTNQ-GBXCKJPGSA-N 0.000 description 2
- GACCQESUPVGTNQ-RDPSFJRHSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[[(1s,2s)-2-hydroxycyclohexyl]methyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC[C@H]2[C@H](CCCC2)O)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 GACCQESUPVGTNQ-RDPSFJRHSA-N 0.000 description 2
- JIWWRNRQEPHLEC-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-cyclopropyl-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 JIWWRNRQEPHLEC-UHFFFAOYSA-N 0.000 description 2
- RSYKEOGSQBQGDI-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-ethyl-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 RSYKEOGSQBQGDI-UHFFFAOYSA-N 0.000 description 2
- ADPDFXUXGUPZRC-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-methyl-3-(2-pyrrolidin-1-ylethoxy)benzamide Chemical compound C1CCCN1CCOC1=CC(C(=O)NC)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 ADPDFXUXGUPZRC-UHFFFAOYSA-N 0.000 description 2
- OBQFUKADXFMQBU-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-methyl-3-propan-2-yloxybenzamide Chemical compound CC(C)OC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 OBQFUKADXFMQBU-UHFFFAOYSA-N 0.000 description 2
- AHZMZOHGUPXOFF-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 AHZMZOHGUPXOFF-UHFFFAOYSA-N 0.000 description 2
- PGRLSIQDOIZYFK-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)oxy]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1OC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 PGRLSIQDOIZYFK-UHFFFAOYSA-N 0.000 description 2
- DRNBPIHQMIFLMY-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-ethyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-methylbenzamide Chemical compound N1=C2N(C3CCCC3)CCC(=O)N(CC)C2=CN=C1NC1=CC=C(C(=O)NC)C=C1OC DRNBPIHQMIFLMY-UHFFFAOYSA-N 0.000 description 2
- OPDVUYIVVLYJPK-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclobutane]-2-yl)amino]-3-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCN(C)CC2)=CC=C1NC(N=C1N(C2CCCC2)C2)=NC=C1N(C)C(=O)C12CCC1 OPDVUYIVVLYJPK-UHFFFAOYSA-N 0.000 description 2
- QCPACNCZCBQULP-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclobutane]-2-yl)amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C2(CCC2)CN2C3CCCC3)C2=N1 QCPACNCZCBQULP-UHFFFAOYSA-N 0.000 description 2
- YWBDFIZWILGVOS-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C2(CC2)CN2C3CCCC3)C2=N1 YWBDFIZWILGVOS-UHFFFAOYSA-N 0.000 description 2
- YPEQMMVXFAIRAL-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-3-methoxy-n-propan-2-ylbenzamide Chemical compound COC1=CC(C(=O)NC(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C2(CC2)CN2C3CCCC3)C2=N1 YPEQMMVXFAIRAL-UHFFFAOYSA-N 0.000 description 2
- LTTKRYZWUXEXIF-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-n-(1-hydroxy-2-methylpropan-2-yl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC(C)(C)CO)=CC=C1NC1=NC=C(N(C)C(=O)C2(CC2)CN2C3CCCC3)C2=N1 LTTKRYZWUXEXIF-UHFFFAOYSA-N 0.000 description 2
- DVGIMOYXCDUTFN-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-n-(3,3-difluorocyclobutyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CC(F)(F)C2)=CC=C1NC(N=C1N(C2CCCC2)C2)=NC=C1N(C)C(=O)C12CC1 DVGIMOYXCDUTFN-UHFFFAOYSA-N 0.000 description 2
- FJAILXLMBIGWKE-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-n-(3-hydroxypropyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCCO)=CC=C1NC1=NC=C(N(C)C(=O)C2(CC2)CN2C3CCCC3)C2=N1 FJAILXLMBIGWKE-UHFFFAOYSA-N 0.000 description 2
- DDESFIZPPZSWFR-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-n-(furan-2-ylmethyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC=2OC=CC=2)=CC=C1NC(N=C1N(C2CCCC2)C2)=NC=C1N(C)C(=O)C12CC1 DDESFIZPPZSWFR-UHFFFAOYSA-N 0.000 description 2
- PEAQLXYHCWXLFB-DENIHFKCSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-n-[(1r,2r)-2-hydroxycyclopentyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)N[C@H]2[C@@H](CCC2)O)=CC=C1NC(N=C1N(C2CCCC2)C2)=NC=C1N(C)C(=O)C12CC1 PEAQLXYHCWXLFB-DENIHFKCSA-N 0.000 description 2
- COHHQNBDIDGAKH-UYAOXDASSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-n-[(1r,3r)-3-hydroxycyclopentyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)N[C@H]2C[C@H](O)CC2)=CC=C1NC(N=C1N(C2CCCC2)C2)=NC=C1N(C)C(=O)C12CC1 COHHQNBDIDGAKH-UYAOXDASSA-N 0.000 description 2
- DLWNBIOKUZXVPK-RDPSFJRHSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-n-[[(1s,2s)-2-hydroxycyclohexyl]methyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC[C@H]2[C@H](CCCC2)O)=CC=C1NC(N=C1N(C2CCCC2)C2)=NC=C1N(C)C(=O)C12CC1 DLWNBIOKUZXVPK-RDPSFJRHSA-N 0.000 description 2
- QFMADZODHJVBMJ-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-n-cyclopropyl-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CC2)=CC=C1NC(N=C1N(C2CCCC2)C2)=NC=C1N(C)C(=O)C12CC1 QFMADZODHJVBMJ-UHFFFAOYSA-N 0.000 description 2
- MGUVLMQHDOHABH-UHFFFAOYSA-N 4-[(9-cyclopentyl-7-ethyl-5-methyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-methylbenzamide Chemical compound C12=NC(NC=3C(=CC(=CC=3)C(=O)NC)OC)=NC=C2N(C)C(=O)C(CC)CN1C1CCCC1 MGUVLMQHDOHABH-UHFFFAOYSA-N 0.000 description 2
- DWLVVFKOYCAZQQ-UHFFFAOYSA-N 4-[[9-(2,2-dimethylpropyl)-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2CC(C)(C)C)C2=N1 DWLVVFKOYCAZQQ-UHFFFAOYSA-N 0.000 description 2
- VSFSVINYPLPWDE-UHFFFAOYSA-N 4-[[9-(3,3-difluorocyclobutyl)-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(oxan-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCOCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CC(F)(F)C1 VSFSVINYPLPWDE-UHFFFAOYSA-N 0.000 description 2
- NFCXFBDQSKTOQA-UHFFFAOYSA-N 4-[[9-(3,3-difluorocyclobutyl)-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CC(F)(F)C3)C2=N1 NFCXFBDQSKTOQA-UHFFFAOYSA-N 0.000 description 2
- PQQNOGZRKJRGGW-UHFFFAOYSA-N 4-[[9-(3-bicyclo[2.2.1]heptanyl)-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3C4CCC(C4)C3)C2=N1 PQQNOGZRKJRGGW-UHFFFAOYSA-N 0.000 description 2
- VVKHOINIIWXMIS-UHFFFAOYSA-N 4-[[9-(3-chlorophenyl)-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C=3C=C(Cl)C=CC=3)C2=N1 VVKHOINIIWXMIS-UHFFFAOYSA-N 0.000 description 2
- VKRHQNUTSRSYOJ-UHFFFAOYSA-N 4-[[9-(cyclobutylmethyl)-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2CC3CCC3)C2=N1 VKRHQNUTSRSYOJ-UHFFFAOYSA-N 0.000 description 2
- UOVJMKOMRYZVHZ-UHFFFAOYSA-N 4-[[9-(cyclopropylmethyl)-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2CC3CC3)C2=N1 UOVJMKOMRYZVHZ-UHFFFAOYSA-N 0.000 description 2
- OELJXBPNBSQGRL-UHFFFAOYSA-N 4-[[9-[(2,2-difluorocyclopropyl)methyl]-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2CC3C(C3)(F)F)C2=N1 OELJXBPNBSQGRL-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- LMJXSOYPAOSIPZ-UHFFFAOYSA-N 4-sulfanylbenzoic acid Chemical compound OC(=O)C1=CC=C(S)C=C1 LMJXSOYPAOSIPZ-UHFFFAOYSA-N 0.000 description 2
- MZBUGUZWGYPLOY-UHFFFAOYSA-N 5-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-1h-indole-2,3-dione Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C=C4C(=O)C(=O)NC4=CC=3)N=C2N1C1CCCC1 MZBUGUZWGYPLOY-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- NEDIGACWKVQDAE-UHFFFAOYSA-N 9-cyclopentyl-2-(1h-indazol-4-ylamino)-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C=4C=NNC=4C=CC=3)N=C2N1C1CCCC1 NEDIGACWKVQDAE-UHFFFAOYSA-N 0.000 description 2
- XBIRNKAGDXWNEE-UHFFFAOYSA-N 9-cyclopentyl-2-(2-methoxyanilino)-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 XBIRNKAGDXWNEE-UHFFFAOYSA-N 0.000 description 2
- OWBGXZSPBDOPSA-UHFFFAOYSA-N 9-cyclopentyl-2-(2-methoxyanilino)-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC=CC=C1NC1=NC=C(N(C)C(=O)CCN2C3CCCC3)C2=N1 OWBGXZSPBDOPSA-UHFFFAOYSA-N 0.000 description 2
- YLHDIJWAOXSOPZ-UHFFFAOYSA-N 9-cyclopentyl-2-(4-imidazol-1-ylanilino)-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=C1)=CC=C1N1C=CN=C1 YLHDIJWAOXSOPZ-UHFFFAOYSA-N 0.000 description 2
- YIZGQIYSDRSLFM-UHFFFAOYSA-N 9-cyclopentyl-2-[2-methoxy-4-(morpholine-4-carbonyl)anilino]-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(C(=O)N2CCOCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 YIZGQIYSDRSLFM-UHFFFAOYSA-N 0.000 description 2
- INMCUILBZKDOGT-UHFFFAOYSA-N 9-cyclopentyl-2-[2-methoxy-4-(piperazine-1-carbonyl)anilino]-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(C(=O)N2CCNCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1CCCC1 INMCUILBZKDOGT-UHFFFAOYSA-N 0.000 description 2
- IEYMZTMKPSXFCD-UHFFFAOYSA-N 9-cyclopentyl-2-[3-(3-cyclopropyl-3-fluoroazetidine-1-carbonyl)anilino]-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=1)=CC=CC=1C(=O)N(C1)CC1(F)C1CC1 IEYMZTMKPSXFCD-UHFFFAOYSA-N 0.000 description 2
- AZNAHNPYPQQOCZ-UHFFFAOYSA-N 9-cyclopentyl-2-[4-(1h-imidazol-2-yl)-2-methoxyanilino]-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(C=2NC=CN=2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 AZNAHNPYPQQOCZ-UHFFFAOYSA-N 0.000 description 2
- HGJKCKDTBPBNKV-UHFFFAOYSA-N 9-cyclopentyl-2-[4-(4,5-dihydro-1h-imidazol-2-yl)-2-methoxyanilino]-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(C=2NCCN=2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 HGJKCKDTBPBNKV-UHFFFAOYSA-N 0.000 description 2
- JHNVOCWTAOLIKQ-UHFFFAOYSA-N 9-cyclopentyl-2-[4-(5,5-dimethyl-1,4-dihydroimidazol-2-yl)-2-methoxyanilino]-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(C=2NC(C)(C)CN=2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 JHNVOCWTAOLIKQ-UHFFFAOYSA-N 0.000 description 2
- IPTHYFGRNIZZSE-SFHVURJKSA-N 9-cyclopentyl-2-[4-[(3s)-3-fluoropyrrolidine-1-carbonyl]-2-methoxyanilino]-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(C(=O)N2C[C@@H](F)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 IPTHYFGRNIZZSE-SFHVURJKSA-N 0.000 description 2
- QWBAETPQSDDDRX-LJQANCHMSA-N 9-cyclopentyl-2-[[(1r)-2,3-dihydro-1h-inden-1-yl]amino]-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(N[C@H]3C4=CC=CC=C4CC3)N=C2N1C1CCCC1 QWBAETPQSDDDRX-LJQANCHMSA-N 0.000 description 2
- UWYFNNNOAAICEE-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-(2-phenylethylamino)-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NCCC1=CC=CC=C1 UWYFNNNOAAICEE-UHFFFAOYSA-N 0.000 description 2
- CMPWMQURSYHUSO-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-(3-pyridin-3-ylanilino)-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=1)=CC=CC=1C1=CC=CN=C1 CMPWMQURSYHUSO-UHFFFAOYSA-N 0.000 description 2
- LFOXUNWCSGGHNO-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-(4-morpholin-4-ylanilino)-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 LFOXUNWCSGGHNO-UHFFFAOYSA-N 0.000 description 2
- AHLAPSWQDYUHJX-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-([1,2,4]triazolo[1,5-a]pyridin-8-ylamino)-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C4=NC=NN4C=CC=3)N=C2N1C1CCCC1 AHLAPSWQDYUHJX-UHFFFAOYSA-N 0.000 description 2
- OLAGZSFZIQUOGG-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[(1-methyl-2-oxo-3h-indol-5-yl)amino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C=1C=C2N(C)C(=O)CC2=CC=1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 OLAGZSFZIQUOGG-UHFFFAOYSA-N 0.000 description 2
- MTBYUKCPWJAZGK-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[(1-methylindazol-5-yl)amino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C=C4C=NN(C)C4=CC=3)N=C2N1C1CCCC1 MTBYUKCPWJAZGK-UHFFFAOYSA-N 0.000 description 2
- ZEIZNAXQTZMEMH-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[(1-methylsulfonyl-2,3-dihydroindol-5-yl)amino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C=C4CCN(C4=CC=3)S(C)(=O)=O)N=C2N1C1CCCC1 ZEIZNAXQTZMEMH-UHFFFAOYSA-N 0.000 description 2
- JWQRPCGCWLWDOS-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[(2-methylindazol-7-yl)amino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C4=NN(C)C=C4C=CC=3)N=C2N1C1CCCC1 JWQRPCGCWLWDOS-UHFFFAOYSA-N 0.000 description 2
- FTLZZLNMUOOARC-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[(2-oxo-1,3-dihydrobenzimidazol-5-yl)amino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C=C4NC(=O)NC4=CC=3)N=C2N1C1CCCC1 FTLZZLNMUOOARC-UHFFFAOYSA-N 0.000 description 2
- GZKYXJAZERABLC-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[(3-oxo-1,2-dihydroindazol-5-yl)amino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C=C4C(=O)NNC4=CC=3)N=C2N1C1CCCC1 GZKYXJAZERABLC-UHFFFAOYSA-N 0.000 description 2
- FOBWLWPQHWKZNU-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[(4-methyl-6-oxo-1h-pyridin-3-yl)amino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC1=CNC(=O)C=C1C FOBWLWPQHWKZNU-UHFFFAOYSA-N 0.000 description 2
- WCRWXDHRPRRYIJ-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[(6-oxo-1h-pyridin-3-yl)amino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC=1C=CC(=O)NC=1 WCRWXDHRPRRYIJ-UHFFFAOYSA-N 0.000 description 2
- OQBLOYIJTLTUBJ-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[3-(1h-pyrazol-5-yl)anilino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=1)=CC=CC=1C=1C=CNN=1 OQBLOYIJTLTUBJ-UHFFFAOYSA-N 0.000 description 2
- YRLXSNRLEZZNCJ-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[3-(2-oxopyrrolidin-1-yl)anilino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=1)=CC=CC=1N1CCCC1=O YRLXSNRLEZZNCJ-UHFFFAOYSA-N 0.000 description 2
- UYKGXIJUXWNSDF-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[4-(1,2,4-triazol-1-yl)anilino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=C1)=CC=C1N1C=NC=N1 UYKGXIJUXWNSDF-UHFFFAOYSA-N 0.000 description 2
- PTQFWIUDQXVTAI-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[4-(1h-pyrazol-5-yl)anilino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=C1)=CC=C1C=1C=CNN=1 PTQFWIUDQXVTAI-UHFFFAOYSA-N 0.000 description 2
- SAHXMYJTBCVCQM-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[4-(4-methylpiperazin-1-yl)anilino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 SAHXMYJTBCVCQM-UHFFFAOYSA-N 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- LKIBYWZKLWYZHS-UHFFFAOYSA-N C1C(OC)=CC=CC1(C(N)=O)C1CCN(C(C)C)CC1 Chemical compound C1C(OC)=CC=CC1(C(N)=O)C1CCN(C(C)C)CC1 LKIBYWZKLWYZHS-UHFFFAOYSA-N 0.000 description 2
- OTSKATSCNARLPM-UHFFFAOYSA-N C1C(OC)=CC=CC1(C(N)=O)C1CCN(CC(C)C)CC1 Chemical compound C1C(OC)=CC=CC1(C(N)=O)C1CCN(CC(C)C)CC1 OTSKATSCNARLPM-UHFFFAOYSA-N 0.000 description 2
- BBSBYCOPAGTPOI-UHFFFAOYSA-N C1CN(CC)CCC1C1(C(N)=O)C=CC=C(OC)C1 Chemical compound C1CN(CC)CCC1C1(C(N)=O)C=CC=C(OC)C1 BBSBYCOPAGTPOI-UHFFFAOYSA-N 0.000 description 2
- XZSYZCHWGONALF-UHFFFAOYSA-N COC1=CC(C(=O)NC)=CC=C1NC1=NC=C2N3C=NN=C3CCN(C3CCCC3)C2=N1 Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C2N3C=NN=C3CCN(C3CCCC3)C2=N1 XZSYZCHWGONALF-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 2
- 201000005262 Chondroma Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 206010073069 Hepatic cancer Diseases 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010005716 Interferon beta-1a Proteins 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- 102100023408 KH domain-containing, RNA-binding, signal transduction-associated protein 1 Human genes 0.000 description 2
- 101710094958 KH domain-containing, RNA-binding, signal transduction-associated protein 1 Proteins 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- CYZAMKJXCMKDNA-UHFFFAOYSA-N N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=C1)=CC=C1N1N=C(C)C=C1O Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=C1)=CC=C1N1N=C(C)C=C1O CYZAMKJXCMKDNA-UHFFFAOYSA-N 0.000 description 2
- 238000006411 Negishi coupling reaction Methods 0.000 description 2
- 201000004404 Neurofibroma Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000006619 Stille reaction Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000012317 TBTU Substances 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000003655 absorption accelerator Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
- 229940063655 aluminum stearate Drugs 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 206010009259 cleft lip Diseases 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 206010016629 fibroma Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002570 interstitial cell Anatomy 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 201000002250 liver carcinoma Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 2
- 235000019793 magnesium trisilicate Nutrition 0.000 description 2
- 229940099273 magnesium trisilicate Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- FDKVUTDHFXROQC-UHFFFAOYSA-N methyl 3-[(2-chloro-5-nitropyrimidin-4-yl)-cyclopentylamino]propanoate Chemical compound N=1C(Cl)=NC=C([N+]([O-])=O)C=1N(CCC(=O)OC)C1CCCC1 FDKVUTDHFXROQC-UHFFFAOYSA-N 0.000 description 2
- KUOFPKMWTNCZCS-UHFFFAOYSA-N methyl n-[4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxyphenyl]carbamate Chemical compound COC1=CC(NC(=O)OC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 KUOFPKMWTNCZCS-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- URIITZNDQCGUGM-UHFFFAOYSA-N n-(1-tert-butylpiperidin-4-yl)-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CCN(CC2)C(C)(C)C)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 URIITZNDQCGUGM-UHFFFAOYSA-N 0.000 description 2
- DFXZAONFQPBCEF-UHFFFAOYSA-N n-(3-bicyclo[2.2.1]heptanyl)-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2C3CCC(C3)C2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 DFXZAONFQPBCEF-UHFFFAOYSA-N 0.000 description 2
- NERLPHKZMCBFPP-UHFFFAOYSA-N n-(cyclobutylmethyl)-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC2CCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 NERLPHKZMCBFPP-UHFFFAOYSA-N 0.000 description 2
- GTZUOYCYEIDXLJ-UHFFFAOYSA-N n-[3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2,6-difluorophenyl]acetamide Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC1=CC=C(F)C(NC(C)=O)=C1F GTZUOYCYEIDXLJ-UHFFFAOYSA-N 0.000 description 2
- TVFDKDNUUGQWPT-UHFFFAOYSA-N n-[3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-4-methoxyphenyl]acetamide Chemical compound COC1=CC=C(NC(C)=O)C=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 TVFDKDNUUGQWPT-UHFFFAOYSA-N 0.000 description 2
- JOVONCGECJJCJS-UHFFFAOYSA-N n-[3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-4-methylphenyl]acetamide Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC1=CC(NC(C)=O)=CC=C1C JOVONCGECJJCJS-UHFFFAOYSA-N 0.000 description 2
- GKMQAKLERGMNOO-UHFFFAOYSA-N n-[3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]phenyl]-1-methylpiperidine-4-carboxamide Chemical compound C1CN(C)CCC1C(=O)NC1=CC=CC(NC=2N=C3N(C4CCCC4)CC(C)(C)C(=O)N(C)C3=CN=2)=C1 GKMQAKLERGMNOO-UHFFFAOYSA-N 0.000 description 2
- SUYONVDRSQXPDM-UHFFFAOYSA-N n-[3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]phenyl]-2-methoxyacetamide Chemical compound COCC(=O)NC1=CC=CC(NC=2N=C3N(C4CCCC4)CC(C)(C)C(=O)N(C)C3=CN=2)=C1 SUYONVDRSQXPDM-UHFFFAOYSA-N 0.000 description 2
- KEHPJDAEOSZPKG-UHFFFAOYSA-N n-[3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]phenyl]-n-methylacetamide Chemical compound CC(=O)N(C)C1=CC=CC(NC=2N=C3N(C4CCCC4)CC(C)(C)C(=O)N(C)C3=CN=2)=C1 KEHPJDAEOSZPKG-UHFFFAOYSA-N 0.000 description 2
- WBFJTASCAQNZSH-UHFFFAOYSA-N n-[3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]phenyl]acetamide Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC1=CC=CC(NC(C)=O)=C1 WBFJTASCAQNZSH-UHFFFAOYSA-N 0.000 description 2
- QGKSRWRRIZOPQW-UHFFFAOYSA-N n-[3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]phenyl]benzamide Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=1)=CC=CC=1NC(=O)C1=CC=CC=C1 QGKSRWRRIZOPQW-UHFFFAOYSA-N 0.000 description 2
- AVRASPVISQVYMX-UHFFFAOYSA-N n-[3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]phenyl]cyclobutanecarboxamide Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=1)=CC=CC=1NC(=O)C1CCC1 AVRASPVISQVYMX-UHFFFAOYSA-N 0.000 description 2
- HJSLFIGEHHAOAS-UHFFFAOYSA-N n-[3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]phenyl]methanesulfonamide Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC1=CC=CC(NS(C)(=O)=O)=C1 HJSLFIGEHHAOAS-UHFFFAOYSA-N 0.000 description 2
- BFPLNSSDOQLDSU-UHFFFAOYSA-N n-[3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]phenyl]piperidine-1-carboxamide Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=1)=CC=CC=1NC(=O)N1CCCCC1 BFPLNSSDOQLDSU-UHFFFAOYSA-N 0.000 description 2
- MDKLMEWQVFJKQC-UHFFFAOYSA-N n-[4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxyphenyl]-2-methoxyacetamide Chemical compound COC1=CC(NC(=O)COC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 MDKLMEWQVFJKQC-UHFFFAOYSA-N 0.000 description 2
- NQSOKLXJWYIJHD-UHFFFAOYSA-N n-[4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]phenyl]-2,2,2-trifluoroacetamide Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC1=CC=C(NC(=O)C(F)(F)F)C=C1 NQSOKLXJWYIJHD-UHFFFAOYSA-N 0.000 description 2
- KVDADAFWXJPUDS-UHFFFAOYSA-N n-[4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]phenyl]-n-methylacetamide Chemical compound C1=CC(N(C(C)=O)C)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 KVDADAFWXJPUDS-UHFFFAOYSA-N 0.000 description 2
- MHFUMWJSCYFZQG-UHFFFAOYSA-N n-[4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]phenyl]acetamide Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC1=CC=C(NC(C)=O)C=C1 MHFUMWJSCYFZQG-UHFFFAOYSA-N 0.000 description 2
- XGRBKPWEJYZQGU-UHFFFAOYSA-N n-[5-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-methylphenyl]acetamide Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC1=CC=C(C)C(NC(C)=O)=C1 XGRBKPWEJYZQGU-UHFFFAOYSA-N 0.000 description 2
- LVXGGSTXTLXQMQ-UHFFFAOYSA-N n-cyclobutyl-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 LVXGGSTXTLXQMQ-UHFFFAOYSA-N 0.000 description 2
- GZOUZDNUISIKSY-KRWDZBQOSA-N n-cyclobutyl-4-[[(7s)-9-cyclopentyl-7-ethyl-5-methyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzamide Chemical compound C([C@@H](C(N(C)C1=CN=C(NC=2C(=CC(=CC=2)C(=O)NC2CCC2)OC)N=C11)=O)CC)N1C1CCCC1 GZOUZDNUISIKSY-KRWDZBQOSA-N 0.000 description 2
- APSFVEJERQFSRC-UHFFFAOYSA-N n-cyclohexyl-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CCCCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 APSFVEJERQFSRC-UHFFFAOYSA-N 0.000 description 2
- JQNVMLKGUBCNHT-UHFFFAOYSA-N n-cyclopentyl-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CCCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 JQNVMLKGUBCNHT-UHFFFAOYSA-N 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 239000004533 oil dispersion Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229950008679 protamine sulfate Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000005956 quaternization reaction Methods 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 201000002314 small intestine cancer Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- TVOCNVFZKONUGK-UHFFFAOYSA-N tert-butyl 3-[[3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]benzoyl]amino]azetidine-1-carboxylate Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=1)=CC=CC=1C(=O)NC1CN(C(=O)OC(C)(C)C)C1 TVOCNVFZKONUGK-UHFFFAOYSA-N 0.000 description 2
- MDPLZVKOZLVKEJ-UHFFFAOYSA-N tert-butyl 4-[[4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)methyl]-3-methoxybenzoyl]amino]piperidine-1-carboxylate Chemical compound COC1=CC(C(=O)NC2CCN(CC2)C(=O)OC(C)(C)C)=CC=C1CC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 MDPLZVKOZLVKEJ-UHFFFAOYSA-N 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 125000004001 thioalkyl group Chemical group 0.000 description 2
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- DOMQFIFVDIAOOT-ROUUACIJSA-N (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide Chemical compound COC1=C(C(=CC=C1)OC)N1C(=NN=C1C=1C=NC=C(C=1)C)NS(=O)(=O)[C@@H](C)[C@H](C)C1=NC=C(C=N1)C DOMQFIFVDIAOOT-ROUUACIJSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- POXWDTQUDZUOGP-UHFFFAOYSA-N 1h-1,4-diazepine Chemical compound N1C=CC=NC=C1 POXWDTQUDZUOGP-UHFFFAOYSA-N 0.000 description 1
- DWNGVJVMHQRPCC-UHFFFAOYSA-N 2-(2-methoxyanilino)-5,9-dimethyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC=CC=C1NC1=NC=C(N(C)C(=O)CCN2C)C2=N1 DWNGVJVMHQRPCC-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- UHTQHHLSGVOGQR-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-4-ium-1-yl]ethanesulfonate Chemical compound OCCN1CCN(CCS(O)(=O)=O)CC1.OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 UHTQHHLSGVOGQR-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- KGUHUVQIJHGHLX-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridin-5-amine Chemical compound NC1=CC=C2NN=NC2=N1 KGUHUVQIJHGHLX-UHFFFAOYSA-N 0.000 description 1
- FSUYMKXZLQOFQY-UHFFFAOYSA-N 3,4-dihydro-1,2-benzodithiine Chemical compound C1=CC=C2SSCCC2=C1 FSUYMKXZLQOFQY-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- IAESHQLORVVSTM-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)sulfanyl]benzoic acid Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1SC1=CC=C(C(O)=O)C=C1 IAESHQLORVVSTM-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- JNFGLYJROFAOQP-UHFFFAOYSA-N 4-amino-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1N JNFGLYJROFAOQP-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- YZUFMZSZWFLZDH-UHFFFAOYSA-N 9-benzyl-2-chloro-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(Cl)N=C2N1CC1=CC=CC=C1 YZUFMZSZWFLZDH-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- FOKSQPBKSFBTBZ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1NC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC2(C)C)C3CCCC3)c1N(C)C2=O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1NC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC2(C)C)C3CCCC3)c1N(C)C2=O)=O)=O FOKSQPBKSFBTBZ-UHFFFAOYSA-N 0.000 description 1
- WSFFEQOBKFCVFA-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1NC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC2)C3CCCC3)c1N(C)C2=O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1NC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC2)C3CCCC3)c1N(C)C2=O)=O)=O WSFFEQOBKFCVFA-UHFFFAOYSA-N 0.000 description 1
- YITBTQBRZJZBGW-UHFFFAOYSA-N CC(C)(CN(C(CC1)CC1c1cc(NC(c(cc2)cc(OC)c2Nc(nc2)n3)=O)n[nH]1)c3c2N1C)C1=O Chemical compound CC(C)(CN(C(CC1)CC1c1cc(NC(c(cc2)cc(OC)c2Nc(nc2)n3)=O)n[nH]1)c3c2N1C)C1=O YITBTQBRZJZBGW-UHFFFAOYSA-N 0.000 description 1
- ZNFFJMXGCBIZTO-XUTJKUGGSA-N CC(C)(CN(C1=CCCC1)c(nc(Nc(ccc(C(N[C@H](CC1)CC[C@@H]1O)=O)c1)c1[O]=C)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1=CCCC1)c(nc(Nc(ccc(C(N[C@H](CC1)CC[C@@H]1O)=O)c1)c1[O]=C)nc1)c1N1C)C1=O ZNFFJMXGCBIZTO-XUTJKUGGSA-N 0.000 description 1
- DNKFEIHYIKJNCO-UHFFFAOYSA-N CC(C)(CN(C1C=CCC1)c(nc(Nc1ccccc1)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1C=CCC1)c(nc(Nc1ccccc1)nc1)c1N1C)C1=O DNKFEIHYIKJNCO-UHFFFAOYSA-N 0.000 description 1
- VFFPTWCWZUWXER-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NCC(CO)O)=O)c1)c1OC)nc1)c1N1C)C1O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NCC(CO)O)=O)c1)c1OC)nc1)c1N1C)C1O VFFPTWCWZUWXER-UHFFFAOYSA-N 0.000 description 1
- OXXJYEQIPPCKQH-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NCC1CCOCC1)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NCC1CCOCC1)=O)c1)c1OC)nc1)c1N1C)C1=O OXXJYEQIPPCKQH-UHFFFAOYSA-N 0.000 description 1
- CKQZCQICBPGDBO-HKWDBMNNSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NC[C@H](CCCC1)[C@@H]1O)=O)c1)c1OC)nc1)c1N1C)C1O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NC[C@H](CCCC1)[C@@H]1O)=O)c1)c1OC)nc1)c1N1C)C1O CKQZCQICBPGDBO-HKWDBMNNSA-N 0.000 description 1
- QWTKTHIBCCBSCV-UYAOXDASSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(N[C@H](CC1)C[C@@H]1O)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(N[C@H](CC1)C[C@@H]1O)=O)c1)c1OC)nc1)c1N1C)C1=O QWTKTHIBCCBSCV-UYAOXDASSA-N 0.000 description 1
- ZBKMGNOJOBNPAA-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(Nc(cccn1)c1OC)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(Nc(cccn1)c1OC)=O)c1)c1OC)nc1)c1N1C)C1=O ZBKMGNOJOBNPAA-UHFFFAOYSA-N 0.000 description 1
- GCQXFBJDTOLBTF-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(Nc1nccnc1)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(Nc1nccnc1)=O)c1)c1OC)nc1)c1N1C)C1=O GCQXFBJDTOLBTF-UHFFFAOYSA-N 0.000 description 1
- ONIVTPSMIVIGHU-UHFFFAOYSA-O CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C([NH3+])=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C([NH3+])=O)c1)c1OC)nc1)c1N1C)C1=O ONIVTPSMIVIGHU-UHFFFAOYSA-O 0.000 description 1
- HNEUKTYZPMHPDO-UHFFFAOYSA-O CC(C)(CN(C1CCCC1)c(nc([NH2+]c(ccc(C(Nc1ncc[s]1)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc([NH2+]c(ccc(C(Nc1ncc[s]1)=O)c1)c1OC)nc1)c1N1C)C1=O HNEUKTYZPMHPDO-UHFFFAOYSA-O 0.000 description 1
- LRLFTGOMOBGFBF-UHFFFAOYSA-O CC(C)(CN(C1CCCC1)c(nc([NH2+]c1cccc2c1nc[nH]2)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc([NH2+]c1cccc2c1nc[nH]2)nc1)c1N1C)C1=O LRLFTGOMOBGFBF-UHFFFAOYSA-O 0.000 description 1
- KHFRBXATZIZXOE-UHFFFAOYSA-N CC(C)(CN(C1CCN(C)CC1)c(nc(Nc(ccc(C(NC)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCN(C)CC1)c(nc(Nc(ccc(C(NC)=O)c1)c1OC)nc1)c1N1C)C1=O KHFRBXATZIZXOE-UHFFFAOYSA-N 0.000 description 1
- HGIQFVGANLZKQU-UHFFFAOYSA-N CC(CN(C1CCCC1)c(nc(Nc(ccc(C(NC1CCN(C)CC1)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(CN(C1CCCC1)c(nc(Nc(ccc(C(NC1CCN(C)CC1)=O)c1)c1OC)nc1)c1N1C)C1=O HGIQFVGANLZKQU-UHFFFAOYSA-N 0.000 description 1
- VFBAFXHFFOATDK-UHFFFAOYSA-N CC(CN(C1CCCC1)c(nc(Nc(ccc(C(O)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(CN(C1CCCC1)c(nc(Nc(ccc(C(O)=O)c1)c1OC)nc1)c1N1C)C1=O VFBAFXHFFOATDK-UHFFFAOYSA-N 0.000 description 1
- YEMCNVLASQBVDV-UHFFFAOYSA-N CC(c1ccccc1)NC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC2(C)C)C3CCCC3)c1N(C)C2=O)=O Chemical compound CC(c1ccccc1)NC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC2(C)C)C3CCCC3)c1N(C)C2=O)=O YEMCNVLASQBVDV-UHFFFAOYSA-N 0.000 description 1
- HXRHBOFIVVVXCJ-UHFFFAOYSA-N CC1(C(NC(NC2(C)N(CC3(C)C)C4C=CCCC4)=NC=C2N(C)C3=O)=CC=C2)N2N=CN1 Chemical compound CC1(C(NC(NC2(C)N(CC3(C)C)C4C=CCCC4)=NC=C2N(C)C3=O)=CC=C2)N2N=CN1 HXRHBOFIVVVXCJ-UHFFFAOYSA-N 0.000 description 1
- VWSLLSXLURJCDF-UHFFFAOYSA-N CC1=NCCN1 Chemical compound CC1=NCCN1 VWSLLSXLURJCDF-UHFFFAOYSA-N 0.000 description 1
- FRBWMVPZFAKPOU-UHFFFAOYSA-N CCCN(CC1)CCC1NC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC2(C)C)C3CCCC3)c1N(C)C2O)=O Chemical compound CCCN(CC1)CCC1NC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC2(C)C)C3CCCC3)c1N(C)C2O)=O FRBWMVPZFAKPOU-UHFFFAOYSA-N 0.000 description 1
- HNXAAGSXTCHYMR-UHFFFAOYSA-N CC[IH][IH]CN(c1c(N(C)CC2)nc(Nc(c(OC)c3)ccc3C(NC3CCN(C)CC3)=O)nc1)C2=O Chemical compound CC[IH][IH]CN(c1c(N(C)CC2)nc(Nc(c(OC)c3)ccc3C(NC3CCN(C)CC3)=O)nc1)C2=O HNXAAGSXTCHYMR-UHFFFAOYSA-N 0.000 description 1
- PWOVFKYKHWLQOD-UHFFFAOYSA-N CN(CC1)CCC1NC(c(cc1)ccc1Nc(nc1)nc(N(CC2)C3CCCC3)c1N(C)C2=O)=O Chemical compound CN(CC1)CCC1NC(c(cc1)ccc1Nc(nc1)nc(N(CC2)C3CCCC3)c1N(C)C2=O)=O PWOVFKYKHWLQOD-UHFFFAOYSA-N 0.000 description 1
- PLDKMKLIFOBOSW-UHFFFAOYSA-N CN(c1c(N(CC2)C3CCCC3)nc(Nc(ccc(C(NC3CCNCC3)=O)c3)c3OC)nc1)C2=O Chemical compound CN(c1c(N(CC2)C3CCCC3)nc(Nc(ccc(C(NC3CCNCC3)=O)c3)c3OC)nc1)C2=O PLDKMKLIFOBOSW-UHFFFAOYSA-N 0.000 description 1
- IFGUGZRRPFBJKI-UHFFFAOYSA-N CN(c1c(N(CC2)C3CCCC3)nc(Nc(ccc(C(NCCOC)=O)c3)c3OC)nc1)C2=O Chemical compound CN(c1c(N(CC2)C3CCCC3)nc(Nc(ccc(C(NCCOC)=O)c3)c3OC)nc1)C2=O IFGUGZRRPFBJKI-UHFFFAOYSA-N 0.000 description 1
- COHHQNBDIDGAKH-QSVWIEALSA-N CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(N[C@H](CC2)CC2O)=O)c2)c2OC)nc1)C3=O Chemical compound CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(N[C@H](CC2)CC2O)=O)c2)c2OC)nc1)C3=O COHHQNBDIDGAKH-QSVWIEALSA-N 0.000 description 1
- XBWVKVCSCJYKTP-UHFFFAOYSA-N CNC(c(cc1)cc(OC)c1Nc(nc1)nc(N(C2CCCC2)C2C3CCC2)c1N(C)C3=O)=O Chemical compound CNC(c(cc1)cc(OC)c1Nc(nc1)nc(N(C2CCCC2)C2C3CCC2)c1N(C)C3=O)=O XBWVKVCSCJYKTP-UHFFFAOYSA-N 0.000 description 1
- JWIYBGVEKGCORU-AWEZNQCLSA-N C[C@@H](CN(C1CCCC1)c(nc(Nc(ccc(C(NC)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound C[C@@H](CN(C1CCCC1)c(nc(Nc(ccc(C(NC)=O)c1)c1OC)nc1)c1N1C)C1=O JWIYBGVEKGCORU-AWEZNQCLSA-N 0.000 description 1
- JWIYBGVEKGCORU-CQSZACIVSA-N C[C@H](CN(C1CCCC1)c(nc(Nc(ccc(C(NC)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound C[C@H](CN(C1CCCC1)c(nc(Nc(ccc(C(NC)=O)c1)c1OC)nc1)c1N1C)C1=O JWIYBGVEKGCORU-CQSZACIVSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 101000582926 Dictyostelium discoideum Probable serine/threonine-protein kinase PLK Proteins 0.000 description 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019629 Hepatic adenoma Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000729945 Homo sapiens Serine/threonine-protein kinase PLK2 Proteins 0.000 description 1
- 101000691614 Homo sapiens Serine/threonine-protein kinase PLK3 Proteins 0.000 description 1
- 101000582914 Homo sapiens Serine/threonine-protein kinase PLK4 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical compound O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
- 208000018501 Lymphatic disease Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102100023330 M-phase inducer phosphatase 3 Human genes 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- FEYNFHSRETUBEM-UHFFFAOYSA-N N-[3-(1,1-difluoroethyl)phenyl]-1-(4-methoxyphenyl)-3-methyl-5-oxo-4H-pyrazole-4-carboxamide Chemical compound COc1ccc(cc1)N1N=C(C)C(C(=O)Nc2cccc(c2)C(C)(F)F)C1=O FEYNFHSRETUBEM-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100031462 Serine/threonine-protein kinase PLK2 Human genes 0.000 description 1
- 102100026209 Serine/threonine-protein kinase PLK3 Human genes 0.000 description 1
- 102100030267 Serine/threonine-protein kinase PLK4 Human genes 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 201000008736 Systemic mastocytosis Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010044002 Tonsil cancer Diseases 0.000 description 1
- 208000006842 Tonsillar Neoplasms Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- HPFVBGJFAYZEBE-XNBTXCQYSA-N [(8r,9s,10r,13s,14s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3CC2)C)CC[C@@]11C)CC1OC(=O)CCC1CCCC1 HPFVBGJFAYZEBE-XNBTXCQYSA-N 0.000 description 1
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
- CTCBPRXHVPZNHB-VQFZJOCSSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate;(2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O CTCBPRXHVPZNHB-VQFZJOCSSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 208000002718 adenomatoid tumor Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 125000000320 amidine group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000015322 bone marrow disease Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 230000017225 centriole replication Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- GQQQULCEHJQUJT-UHFFFAOYSA-N ethyl 4-aminopiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(N)CC1 GQQQULCEHJQUJT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 201000002735 hepatocellular adenoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 1
- AHYUCALUVDREAN-UHFFFAOYSA-N methyl 3-(cyclopentylamino)propanoate Chemical compound COC(=O)CCNC1CCCC1 AHYUCALUVDREAN-UHFFFAOYSA-N 0.000 description 1
- NCCWQNGNNMNIRA-UHFFFAOYSA-N methyl 3-[cyclopentyl-(2-methyl-5-nitropyrimidin-4-yl)amino]propanoate Chemical compound N=1C(C)=NC=C([N+]([O-])=O)C=1N(CCC(=O)OC)C1CCCC1 NCCWQNGNNMNIRA-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 230000008600 mitotic progression Effects 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000006082 mold release agent Substances 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 description 1
- VIJWNQRZLJXMTH-UHFFFAOYSA-N n-(azetidin-3-yl)-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CNC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 VIJWNQRZLJXMTH-UHFFFAOYSA-N 0.000 description 1
- ZHEGAZKODCWEBM-UHFFFAOYSA-N n-(cyclohexylmethyl)-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC2CCCCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 ZHEGAZKODCWEBM-UHFFFAOYSA-N 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- NNKPHNTWNILINE-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 NNKPHNTWNILINE-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000034394 regulation of mitosis Effects 0.000 description 1
- 230000009712 regulation of translation Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940106887 risperdal Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- RADGOBKLTHEUQO-UHFFFAOYSA-N ruthenium(4+) Chemical compound [Ru+4] RADGOBKLTHEUQO-UHFFFAOYSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 201000001839 skull cancer Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000020347 spindle assembly Effects 0.000 description 1
- 230000019130 spindle checkpoint Effects 0.000 description 1
- 201000010159 squamous cell papilloma Diseases 0.000 description 1
- 208000017015 squamous papilloma Diseases 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 201000007363 trachea carcinoma Diseases 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77299206P | 2006-02-14 | 2006-02-14 | |
| US60/772,992 | 2006-02-14 | ||
| US83137106P | 2006-07-17 | 2006-07-17 | |
| US60/831,371 | 2006-07-17 | ||
| US84935306P | 2006-10-04 | 2006-10-04 | |
| US60/849,353 | 2006-10-04 | ||
| US87620606P | 2006-12-21 | 2006-12-21 | |
| US60/876,206 | 2006-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080095902A true KR20080095902A (ko) | 2008-10-29 |
Family
ID=38330249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087022521A Abandoned KR20080095902A (ko) | 2006-02-14 | 2007-02-13 | 단백질 키나제의 억제제로서 유용한 디하이드로디아제핀 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7622463B2 (enExample) |
| EP (1) | EP1983987B1 (enExample) |
| JP (2) | JP5243970B2 (enExample) |
| KR (1) | KR20080095902A (enExample) |
| AR (1) | AR059505A1 (enExample) |
| AT (1) | ATE479434T1 (enExample) |
| AU (1) | AU2007215221C1 (enExample) |
| CA (1) | CA2652648C (enExample) |
| DE (1) | DE602007008837D1 (enExample) |
| IL (1) | IL193240A0 (enExample) |
| NO (1) | NO20083918L (enExample) |
| NZ (1) | NZ570530A (enExample) |
| RU (1) | RU2475488C2 (enExample) |
| TW (1) | TW200804389A (enExample) |
| WO (1) | WO2007095188A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220125156A (ko) | 2021-03-04 | 2022-09-14 | 한양대학교 에리카산학협력단 | 피리디닐 피라졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도 |
| KR20230076333A (ko) | 2021-11-24 | 2023-05-31 | 한양대학교 에리카산학협력단 | 이속사졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도 |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200808325A (en) | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| JP5087640B2 (ja) * | 2007-03-22 | 2012-12-05 | 武田薬品工業株式会社 | Ｐｌｋ１阻害剤として有用な置換ピリミドジアゼピン |
| TW200914457A (en) * | 2007-05-31 | 2009-04-01 | Kyowa Hakko Kogyo Kk | Pyrimidodiazepinone derivative |
| MX2009013728A (es) * | 2007-06-15 | 2010-01-25 | Banyu Pharma Co Ltd | Derivados de bicicloanilina. |
| CA2695753A1 (en) * | 2007-08-15 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | Compounds useful as protein kinases inhibitors |
| MX2010003249A (es) * | 2007-09-25 | 2010-11-09 | Takeda Pharmaceutical | Inhibidores de quinasas símil polo. |
| CN101878216B (zh) | 2007-09-28 | 2013-07-10 | 西克拉塞尔有限公司 | 作为蛋白激酶抑制剂的嘧啶衍生物 |
| WO2009067547A1 (en) * | 2007-11-19 | 2009-05-28 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| EP2215091B1 (en) | 2007-12-04 | 2016-03-30 | Nerviano Medical Sciences S.r.l. | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors |
| WO2009153197A1 (en) | 2008-06-18 | 2009-12-23 | F. Hoffmann-La Roche Ag | Halo-substituted pyrimidodiazepines as plkl inhibitors |
| KR20110039278A (ko) | 2008-06-23 | 2011-04-15 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제 |
| CN102076691A (zh) * | 2008-06-23 | 2011-05-25 | 维泰克斯制药公司 | 蛋白激酶抑制剂 |
| NZ593110A (en) | 2008-12-09 | 2013-06-28 | Gilead Sciences Inc | pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS |
| EP2379559B1 (en) | 2009-01-06 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| AU2010232644A1 (en) | 2009-03-31 | 2011-10-20 | Arqule, Inc. | Substituted tetrahydropyrazolo-pyrido-azepin compounds |
| AU2010262905B2 (en) | 2009-06-17 | 2015-04-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| NZ599356A (en) | 2009-09-25 | 2013-08-30 | Vertex Pharma | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors |
| KR20120096474A (ko) | 2009-09-25 | 2012-08-30 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피리미딘 유도체의 제조 방법 |
| US8541407B2 (en) | 2010-03-31 | 2013-09-24 | Arqule, Inc. | Substituted benzo-pyrido-triazolo-diazepine compounds |
| CA2799403C (en) | 2010-05-14 | 2020-01-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
| HUE031073T2 (en) | 2010-05-14 | 2017-06-28 | Dana Farber Cancer Inst Inc | Thieno triazolo-diazepine compounds for the treatment of neoplasia |
| WO2011143657A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Male contraceptive compositions and methods of use |
| US8933070B2 (en) | 2010-07-02 | 2015-01-13 | University Health Network | Methods of targeting PTEN mutant diseases and compositions therefor |
| KR20140014110A (ko) | 2010-12-16 | 2014-02-05 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| US9676792B2 (en) * | 2013-03-15 | 2017-06-13 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone compounds and methods of treating disorders |
| KR20160034379A (ko) | 2013-07-25 | 2016-03-29 | 다나-파버 캔서 인스티튜트 인크. | 전사 인자의 억제제 및 그의 용도 |
| RU2016122654A (ru) | 2013-11-08 | 2017-12-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка |
| ES2741444T3 (es) | 2013-11-13 | 2020-02-11 | Vertex Pharma | Inhibidores de la replicación de virus de la gripe |
| EP3068782B1 (en) | 2013-11-13 | 2018-05-23 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| US10793571B2 (en) | 2014-01-31 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| KR20160111036A (ko) * | 2014-01-31 | 2016-09-23 | 다나-파버 캔서 인스티튜트 인크. | 디아제판 유도체 및 그의 용도 |
| US10150756B2 (en) | 2014-01-31 | 2018-12-11 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| CA2940472A1 (en) | 2014-02-28 | 2015-09-03 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
| GB201411581D0 (en) * | 2014-06-30 | 2014-08-13 | Inst Europ Di Oncologia S R L | Compounds inhibiting the enzyme monopolar spindle 1 kinase, pharmaceutical compositions and uses thereof |
| EA201790024A1 (ru) | 2014-07-11 | 2017-07-31 | Джилид Сайэнс, Инк. | Модуляторы toll-подобных рецепторов для лечения вич |
| RU2017104897A (ru) | 2014-08-08 | 2018-09-10 | Дана-Фарбер Кэнсер Инститьют, Инк. | Производные диазепана и их применения |
| EP3177147A4 (en) | 2014-08-08 | 2018-01-24 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
| US9738646B2 (en) | 2014-09-16 | 2017-08-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
| EA033325B1 (ru) | 2014-10-27 | 2019-09-30 | Тэнша Терапеутикс, Инк. | Ингибиторы бромодомена |
| EP3223821A1 (de) | 2014-11-25 | 2017-10-04 | Bayer Pharma Aktiengesellschaft | Substituierte pyridobenzodiazepinon-derivate und ihre verwendung |
| WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| KR20180051576A (ko) | 2015-09-11 | 2018-05-16 | 다나-파버 캔서 인스티튜트 인크. | 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도 |
| CN108472300A (zh) | 2015-09-11 | 2018-08-31 | 达纳-法伯癌症研究所股份有限公司 | 氰基噻吩并三唑并二氮杂环庚三烯及其用途 |
| PE20181298A1 (es) | 2015-11-25 | 2018-08-07 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| AR121356A1 (es) | 2020-02-18 | 2022-05-11 | Gilead Sciences Inc | Compuestos antivirales |
| ES3028915T3 (en) | 2021-04-16 | 2025-06-20 | Gilead Sciences Inc | Methods of preparing carbanucleosides using amides |
| EP4387977A1 (en) | 2021-08-18 | 2024-06-26 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5638032B2 (enExample) | 1972-08-31 | 1981-09-03 | ||
| US3880855A (en) | 1973-04-16 | 1975-04-29 | Bristol Myers Co | 5,6-DIHYDRO-11-H-pyrimido{8 4,5-b{9 {8 1,4{9 benzodiazepines |
| US3872122A (en) * | 1973-04-16 | 1975-03-18 | Bristol Myers Co | 11 H-Pyrimido{8 4,5-b{9 {8 1,4{9 benzodiazepines |
| JPS51110202A (en) | 1975-03-24 | 1976-09-29 | Susumu Nojima | Denwakyono hyojisochi |
| GB8927872D0 (en) | 1989-12-08 | 1990-02-14 | Beecham Group Plc | Pharmaceuticals |
| US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| MXPA02001108A (es) | 1999-09-15 | 2002-08-20 | Warner Lambert Co | Pieridinonas como inhibidores de la cinasa. |
| SK3792002A3 (en) * | 1999-09-17 | 2003-09-11 | Abbott Gmbh & Co Kg | Kinase inhibitors as therapeutic agents |
| TR200201431T2 (tr) | 1999-11-30 | 2002-09-23 | Pfizer Products Inc. | İmünosupresanlar olarak faydalı 2,4-diaminopirimidin bileşikleri |
| US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
| HRP20040213A2 (en) | 2001-09-04 | 2005-02-28 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments |
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| KR100983462B1 (ko) | 2003-02-26 | 2010-09-27 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 디하이드로프테리디논, 이의 제조방법 및 약제로서의 이의 용도 |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| MX2010003249A (es) | 2007-09-25 | 2010-11-09 | Takeda Pharmaceutical | Inhibidores de quinasas símil polo. |
| JP4941835B2 (ja) | 2007-09-28 | 2012-05-30 | Ｔｏｔｏ株式会社 | キャビネット及びキャビネットの施工方法 |
| CN101878216B (zh) | 2007-09-28 | 2013-07-10 | 西克拉塞尔有限公司 | 作为蛋白激酶抑制剂的嘧啶衍生物 |
| JP5035192B2 (ja) | 2008-09-19 | 2012-09-26 | コニカミノルタアドバンストレイヤー株式会社 | 駆動機構、駆動装置 |
-
2007
- 2007-02-13 DE DE602007008837T patent/DE602007008837D1/de active Active
- 2007-02-13 US US11/706,070 patent/US7622463B2/en active Active
- 2007-02-13 EP EP07750530A patent/EP1983987B1/en active Active
- 2007-02-13 NZ NZ570530A patent/NZ570530A/en unknown
- 2007-02-13 RU RU2008136854/04A patent/RU2475488C2/ru not_active IP Right Cessation
- 2007-02-13 JP JP2008555299A patent/JP5243970B2/ja active Active
- 2007-02-13 CA CA2652648A patent/CA2652648C/en active Active
- 2007-02-13 TW TW096105339A patent/TW200804389A/zh unknown
- 2007-02-13 KR KR1020087022521A patent/KR20080095902A/ko not_active Abandoned
- 2007-02-13 AU AU2007215221A patent/AU2007215221C1/en not_active Ceased
- 2007-02-13 WO PCT/US2007/003699 patent/WO2007095188A2/en not_active Ceased
- 2007-02-13 AT AT07750530T patent/ATE479434T1/de active
- 2007-02-14 AR ARP070100633A patent/AR059505A1/es unknown
-
2008
- 2008-08-05 IL IL193240A patent/IL193240A0/en unknown
- 2008-09-15 NO NO20083918A patent/NO20083918L/no not_active Application Discontinuation
-
2009
- 2009-09-29 US US12/569,237 patent/US8022202B2/en active Active
-
2011
- 2011-08-10 US US13/206,638 patent/US8394952B2/en active Active
-
2013
- 2013-01-21 US US13/745,968 patent/US20140038935A1/en not_active Abandoned
- 2013-01-23 JP JP2013009857A patent/JP2013067666A/ja not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220125156A (ko) | 2021-03-04 | 2022-09-14 | 한양대학교 에리카산학협력단 | 피리디닐 피라졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도 |
| KR20230076333A (ko) | 2021-11-24 | 2023-05-31 | 한양대학교 에리카산학협력단 | 이속사졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도 |
| KR20230170623A (ko) | 2021-11-24 | 2023-12-19 | 한양대학교 에리카산학협력단 | 이속사졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080167289A1 (en) | 2008-07-10 |
| EP1983987A2 (en) | 2008-10-29 |
| DE602007008837D1 (de) | 2010-10-14 |
| US7622463B2 (en) | 2009-11-24 |
| HK1129298A1 (en) | 2009-11-27 |
| AU2007215221A1 (en) | 2007-08-23 |
| RU2475488C2 (ru) | 2013-02-20 |
| US20100190765A1 (en) | 2010-07-29 |
| AU2007215221C1 (en) | 2013-05-30 |
| NZ570530A (en) | 2011-09-30 |
| NO20083918L (no) | 2008-11-12 |
| CA2652648A1 (en) | 2007-08-23 |
| ATE479434T1 (de) | 2010-09-15 |
| AU2007215221B2 (en) | 2013-01-17 |
| US20140038935A1 (en) | 2014-02-06 |
| JP5243970B2 (ja) | 2013-07-24 |
| TW200804389A (en) | 2008-01-16 |
| JP2013067666A (ja) | 2013-04-18 |
| JP2009526849A (ja) | 2009-07-23 |
| WO2007095188A3 (en) | 2007-10-25 |
| RU2008136854A (ru) | 2010-03-20 |
| EP1983987B1 (en) | 2010-09-01 |
| US20120149898A1 (en) | 2012-06-14 |
| CA2652648C (en) | 2016-10-25 |
| WO2007095188A2 (en) | 2007-08-23 |
| US8022202B2 (en) | 2011-09-20 |
| IL193240A0 (en) | 2009-08-03 |
| US8394952B2 (en) | 2013-03-12 |
| AR059505A1 (es) | 2008-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1983987B1 (en) | Dihydrodiazepines useful as inhibitors of protein kinases | |
| CN101420955B (zh) | 可用作蛋白激酶抑制剂的二氢二氮杂* | |
| US8530489B2 (en) | 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors | |
| EP3672949B9 (en) | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
| JP6526065B2 (ja) | Ｔｙｋ２阻害剤およびその使用 | |
| EP3414252B1 (en) | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | |
| US20040235886A1 (en) | Gyrase inhibitors and uses thereof | |
| TW202233612A (zh) | Ctps1抑制劑及其用途 | |
| IL274762B1 (en) | Novel heterocyclic compounds as prmt5 inhibitors | |
| EA036160B1 (ru) | Гетероарильные соединения и их применение | |
| EP3071205A1 (en) | Benzopiperazine compositions as bet bromodomain inhibitors | |
| US20160083391A1 (en) | Tricyclic piperazine derivative | |
| WO2023104165A1 (zh) | 作为TLR7/8激动剂的吡啶[4,3-d]嘧啶类化合物 | |
| US12053459B2 (en) | CDK2 inhibitors and methods of using the same | |
| US20250270200A1 (en) | Ctps1 inhibitors and uses thereof | |
| HK1129298B (en) | Dihydrodiazepines useful as inhibitors of protein kinases | |
| WO2024092115A2 (en) | Mk2 inhibitors and uses thereof | |
| HK1142267A (en) | 5-cyan0-4- (pyrrolo [2,3b] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20080912 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20120208 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20130710 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20140218 |
|
| PC1904 | Unpaid initial registration fee |